Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine: analysis from the AIDS Clinical Trial Group A5208 trial. Tenofovir disoproxil fumarate (TDF) has been associated with renal insufficiency. Co-administration with boosted protease inhibitors, which increases its exposure, may further increase the risk of renal insufficiency. We compared the incidence of renal events among women taking TDF co-administered with lopinavir/ritonavir (LPV/r) versus those co-administering TDF with nevirapine (NVP). Renal events were defined as a confirmed drop in creatinine clearance associated with a serum creatinine grade 2 or higher, or that leading to treatment modification.
GlobalResearch at UCSF presents the broad scope of health research that is being conducted by UCSF researchers worldwide